Recursion Pharmaceuticals
clinical no approved medical therapy standard of care colectomy during adolescence with or without removal of rectum post colectomy patients still at significant risk of polyps progressing to cancer significant decrease in quality of life post colectomy continued endoscopies and surgical intervention despite progress with surgical management the need for effective therapies for remains high due to continued risk of tumors post surgery disease overview familial adenomatous polyposis | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
107 of 143
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights